Internal Medicine, Gastroenterology · E Patchogue, NY
NPI
1053334490
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
260 Patchogue Yaphank Rd, Suite C
E Patchogue, NY, 11772
Phone (631) 289-0300
Groups this clinician bills Medicare through
Medicare paid, 2024
$144K
1,346 services
Medicare patients, 2024
655
Average age 73
Drug cost, 2024
$942K
2,991 prescriptions
Company payments, 2025
$1,561
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kevin Sano was code 99213 (office e&m - established), 608 times for 387 patients. In total Kevin Sano billed 1,346 services in 18 codes, and Medicare paid $144K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-03-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 608 | 387 | $74.40 | $45K |
| 99214 Office E&M - Established | Office | 153 | 144 | $99.05 | $15K |
| 43239 Upper GI Endoscopy | Facility | 151 | 151 | $87.91 | $13K |
| 99204 Office E&M - New | Office | 124 | 124 | $136.95 | $17K |
| 45385 Colonoscopy - Lesion Removal | Facility | 84 | 83 | $225.49 | $19K |
| 45380 Lower GI Endoscopy - Other | Facility | 75 | 75 | $114.92 | $8,619 |
| 45378 Lower GI Endoscopy - Other | Facility | 71 | 71 | $158.47 | $11K |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 23 | 23 | $206.82 | $4,757 |
| 99203 Office E&M - New | Office | 18 | 18 | $91.05 | $1,639 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 14 | 14 | $214.59 | $3,004 |
By year: 2022 $189K for 1,802 services; 2023 $161K for 1,522 services; 2024 $144K for 1,346 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kevin Sano prescribed most often to Medicare patients was Pantoprazole Sodium, with 573 prescriptions and refills. In total Kevin Sano wrote 2,991 Medicare prescriptions that cost $942K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 573 | 1,529 | 204 | $9,876 |
| Omeprazole Generic | 449 | 1,214 | 165 | $5,942 |
| Dicyclomine Hcl Generic | 304 | 574 | 131 | $6,703 |
| Famotidine Generic | 258 | 694 | 92 | $3,357 |
| Linzess Linaclotide | 244 | 452 | 88 | $232K |
| Lubiprostone Generic | 95 | 167 | 38 | $21K |
| Ondansetron Hcl Generic | 88 | 126 | 32 | $1,401 |
| Clenpiq Sod Picosulf/Mag Ox/Citric Ac | 86 | 86 | 84 | $15K |
| Esomeprazole Magnesium Generic | 57 | 123 | 19 | $2,172 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 56 | 56 | 55 | $3,169 |
| Sucralfate Generic | 48 | 73 | 27 | $8,663 |
| Trulance Plecanatide | 43 | 65 | 12 | $33K |
| Lansoprazole Generic | 41 | 113 | 15 | $1,230 |
| Motegrity Prucalopride Succinate | 41 | 93 | Under 11 | $46K |
| Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl | 33 | 33 | 32 | $528 |
Brand drugs: 691 claims; generic drugs: 2,300 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kevin Sano $1,561 ($1,561 in general payments such as food, travel and fees) from 12 companies. The largest payer was Salix Pharmaceuticals, a division of Bausch Health US, LLC with $489.
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 57 | $489 |
| Abbvie Inc. ABBV | 35 | $435 |
| Ardelyx, Inc. ARDX | 8 | $163 |
| Madrigal Pharmaceuticals MDGL | 7 | $149 |
| Pfizer Inc. PFE | 5 | $92.51 |
| Phathom Pharmaceuticals, Inc. PHAT | 6 | $70.1 |
| Braintree Laboratories, Inc. | 1 | $40.91 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $39.6 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 1 | $23.21 |
| Genzyme Corporation SNY | 1 | $20.71 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.